Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans

Dermatology

Volumn 216, Issue 2, 2008, Pages 93-103

  Glatz, Martin ^a   Fingerle, Volker ^b   Wilske, Bettina ^b   Ambros Rudolph, Christina ^a   Kerl, Helmut ^a   Müllegger, Robert R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Borrelia burgdorferi; Erythema migrans; Immunoblot; Lyme borreliosis; Variable major protein like sequence expressed antigen

Indexed keywords

BACTERIAL ANTIGEN; DECORIN BINDING PROTEIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OUTER SURFACE PROTEIN C; PROTEIN; PROTEIN P100; PROTEIN P39; PROTEIN P58; UNCLASSIFIED DRUG; VARIABLE MAJOR PROTEIN LIKE SEQUENCE EXPRESSED ANTIGEN;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BORRELIA BURGDORFERI; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; ERYTHEMA CHRONICUM MIGRANS; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOREACTIVITY; LYME DISEASE; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORRELIA BURGDORFERI; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38549127683     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111505     Document Type: Article

References (60)

1. Steere AC: Lyme disease. N Engl J Med 2001;345:115-125.
2. Müllegger RR: Dermatological manifestations of Lyme borreliosis. Eur J Dermatol 2004;14:296-309.
3. Aberer E, Kahofer P, Binder B, Kinaciyan T, Schauperl H, Berghold A: Comparison of a two- to three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin. Dermatology 2006;212:160-167.
4. Hulshof MM, Vandenbrouke JP, Nohlmans LM, Spanjaard L, Bavnick JN, Dijkmans BA: Long-term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans. Arch Dermatol 1997;133:33-37.
5. Weber K: Treatment failure in erythema migrans - A review. Infection 1996;24:73-75.
6. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
7. Picken MM, Picken RN, Han D, Cheng Y, Ruzic-Sabljic E, Cimperman J, Maraspin V, Lotric-Furlan S, Strle F: A two-year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis. Mol Pathol 1997;50:186-193.
8. Lebech AM, Hansen K, Bandrup F, Clemmensen O, Halkier-Sorensen L: Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn 2000;5:139-150.
9. Glatz M, Golestani M, Kerl H, Müllegger RR: Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy of erythema migrans. Long-term follow-up study of 113 patients. Arch Dermatol 2006;142:862-868.
10. Dressler F, Whalen JA, Reinhardt BN, Steere AC: Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993;167:392-400.
11. Ledue TB, Collins MF, Craig WY: New laboratory guidelines for serologic diagnosis of Lyme disease: evaluation of the two-test protocol. J Clin Microbiol 1996;34:2343-2350.
12. Schulte-Spechtel U, Lehnert G, Liegl G, Fingerle V, Heimerl C, Johnson BJ, Wilske B: Significant improvement of the recombinant Borrelia -specific immunoglobulin G immunoblot test by the addition of VlsE and a DbpA homologue derived from Borrelia garinii for the diagnosis of early neuroborreliosis. J Clin Microbiol 2003;41:1299-1303.
13. Aguero-Rosenfeld ME, Wang G, Schartz I, Wormser GP: Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005;18:484-509.
14. Stanek G, O'Connell S, Cimmino M, Aberer E, Kristoferitsch W, Granstrom M, Guy E, Gray J: European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 1996;108:741-747.
15. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC: Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002;136:421-428.
16. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft B: Practice guidelines for the treatment of Lyme disease: guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2000;31(suppl):1-14.
17. Wilske B, Fingerle V, Herzer P, Hofmann A, Lehnert G, Peters H, Pfister HW, Preac-Mursic V, Soutschek E, Weber K: Recombinant immunoblot in the serodiagnosis of Lyme borreliosis: comparison with indirect immunofluorescence and enzyme-linked immunosorbent assay. Med Microbiol Immunol 1993;182:255-270.
18. Wilske B, Fingerle V, Preac-Mursic V, Jauris-Heipke S, Hofmann A, Loy H, Pfister HW, Rossler D, Soutschek E: Immunoblot using recombinant antigens derived from different genospecies of Borrelia burgdorferi sensu lato. Med Microbiol Immunol 1994;183:43-59.
19. Roessler D, Hauser U, Wilske B: Heterogeneity of BmpA (p39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis. J Clin Microbiol 1997;35:2752-2758.
20. Jauris-Heipke S, Rossle B, Wanner G, Habermann C, Rossler D, Fingerle V, Lehnert G, Lobentanzer R, Pradel I, Hillenbrand B, Schulte-Spechtel U, Wilske B: Osp17, a novel immunodominant outer surface protein of Borrelia afzelii: recombinant expression in Escherichia coli and its use as a diagnostic antigen for serodiagnosis of Lyme borreliosis. Med Microbiol Immunol 1999;187:213-219.
21. Wilske B, Habermann C, Fingerle V, Hillenbrand B, Jauris-Heipke S, Lehnert G, Pradel I, Rossler D, Schulte-Spechtel U: An improved recombinant IgG immunoblot for serodiagnosis of Lyme borreliosis. Med Microbiol Immunol 1999;188:139-144.
22. Guo BP, Brown EL, Dorward DW, Rosenberg LC, Höök M: Decorin-binding adhesins from Borrelia burgdorferi. Mol Microbiol 1998;30:711-723.
23. Rasiah C, Schiltz E, Reichert J, Vogt A: Purification and characterization of a tryptic peptide of Borrelia burgdorferi flagellin, which reduces cross-reactivity in immunoblots and ELISA. J Gen Microbiol 1992;138:147-154.
24. Wilske B, Preac-Mursic V, Jauris S, Hofmann A, Pradel I, Soutschek E, Schwab W, Will G, Wanner G: Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi. Infect Immun 1993;61:2182-2191.
25. Fung BP, McHugh GL, Leong JM, Steere AC: Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of immunoglobulin M response in the serodiagnosis of early infection. Infect Immun 1994;62:3213-3221.
26. Simpson WJ, Burgdorfer W, Schrumpf ME, Karstens RH, Schwan TG: Antibody to a 39-kilodalton Borrelia burgdorferi antigen (P39) as a marker for infection in experimentally and naturally inoculated animals. J Clin Microbiol 1991;19:236-243.
27. Zhang JR, Hardham JM, Barbour AG, Norris SJ: Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997;89:275-285.
28. Liang FT, Philipp MT: Epitope mapping of the immunodominant invariable region of Borrelia burgdorferi VlsE in three host species. Infect Immun 2000;68:2349-2353.
29. Bono JL, Tilly K, Stevenson B, Hogan D, Rosa P: Oligopeptide permease in Borrelia burgdorferi: putative peptide-binding components encoded by both chromosomal and plasmid loci. Microbiology 1998;44:1033-1044.
30. Volkman DJ, Luft BJ, Gorevic PD, Schultz J, Padovano L: Characterization of an immunoreactive 93-kDa core protein of Borrelia burgdorferi with a human IgG monoclonal antibody. J Immunol 1991;146:3177-3182.
31. Wilske B, Zoeller L, Brade V, Eiffert H, Goebel UB, Stanek G, Pfister HW: Quality Standards for the Microbiological Diagnosis of Infectious Diseases 12: Lyme Borreliosis. German Society for Hygiene and Microbiology. Munich, Urban & Fischer, 2000.
32. Goettner G, Schulte-Spechtel U, Hillermann R, Liegl G, Wilske B, Fingerle V: Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. J Clin Microbiol 2005;43:3602-3609.
33. Hansen K, Hindersson P, Pedersen NS: Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease. J Clin Microbiol 1988;26:338-346.
34. Coleman JL, Benach JL: Isolation of antigenic components from the Lyme disease spirochete: their role in early diagnosis. J Infect Dis 1987;155:756-765.
35. Feder HM Jr, Gerber MA, Luger SW, Ryan RW: Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis 1992;15:788-793.
36. Aguero-Rosenfeld ME, Nowakowski J, McKenna DF, Carbonaro CA, Wormser GP: Serodiagnosis in early Lyme disease. J Clin Microbiol 1993;31:3090-3095.
37. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP, Duray PH, Larson MG, Wright EA, Ginsburg KS, Katz JN, Liang MH: The long-term clinical outcomes of Lyme disease: a population-based retrospective cohort study. Ann Intern Med 1994;121:560-567.
38. Engstrom SM, Shoop E, Johnson RC: Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol 1995;33:419-427.
39. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP: Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996;34:1-9.
40. Ryffel K, Peter O, Rutti B, Suard A, Dayer E: Scored antibody reactivity determined by immunoblotting shows an association between clinical manifestations and presence of Borrelia burgdorferi sensu stricto, B. garinii, B. afzelii , and B. valaisiana in humans. J Clin Microbiol 1999;37:4086-4092.
41. Stanek G, Breier F, Menzinger G, Schaar B, Hafner M, Partsch H: Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three borrelia species. Wien Klin Wochenschr 1999;111:951-956.
42. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC: Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001;33:780-785.
43. Hauser U, Lehnert G, Lobentanzer R, Wilske B: Interpretation criteria for standardized Western blots for three European species of Borrelia burgdorferi sensu lato. J Clin Microbiol 1997;35:1433-1444.
44. Wilske B: Epidemiology and diagnosis of Lyme borreliosis. Ann Med 2005;37:568-579.
45. Hofmann H, Wallich R, Lorenz I, Bechtel M. Comparison of a new line assay using purified and recombinant antigens with a European lysate blot for serodiagnosis of Lyme borreliosis. Int J Med Microbiol 2006;296(suppl 1):288-290.
46. Grodzicki RL, Steere AC: Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using different antigen preparations for diagnosing early Lyme disease. J Infect Dis 1988;15:7790-7797.
47. Magnarelli LA, Ijdo JW, Padula SJ, Flavell RA, Fikrig E: Serologic diagnosis of Lyme borreliosis by using enzyme-linked immunosorbent assays with recombinant antigens. J Clin Microbiol 2000;38: 1735-1739.
48. Sillanpaa H, Lahdenne P, Sarvas H, Arnez M, Steere A, Peltomaa M, Seppala I: Immune responses to borrelial VlsE IR6 peptide variants. Int J Med Microbiol 2007;297: 45-52.
49. Ruzic-Sabljic E, Maraspin V, Cimperman J, Lotric-Furlan S, Strle F: Evaluation of immunofluorescence test (IFT) and immuno (Western) blot (WB) test in patients with erythema migrans. Wien Klin Wochenschr 2002;114:586-590.
50. Bruckbauer HR, Preac-Mursic V, Fuchs R, Wilske B: Cross-reactive proteins of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1992;11:224-232.
51. Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT: Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J Clin Microbiol 1999;37:3990-3996.
52. Magnarelli LA, Lawrenz M, Norris SJ, Fikrig E: Comparative reactivity of human sera to recombinant VlsE and other Borrelia burgdorferi antigens in class-specific enzymelinked immunosorbent assays for Lyme borreliosis. J Med Microbiol 2002;51:649-655.
53. Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD Jr, Philipp MT, Steere AC: Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003;187:1187-1199.
54. Lahdenne P, Panelius J, Saxen H, Heikkila T, Sillanpaa H, Peltomaa M, Arnez M, Huppertz HI, Seppala IJ: Improved serodiagnosis of erythema migrans using novel recombinant borrelial BBK32 antigens. J Med Microbiol 2003;52:563-567.
55. Marangoni A, Sambri V, Accardo S, Cavrini F, Mondardini V, Moroni A, Storni E, Cevenini R: A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol 2006;13:525-529.
56. Wilske B, Preac-Mursic V: Microbiological diagnosis of Lyme borreliosis; in Weber K, Burgdorfer W (eds): Aspects of Lyme Borreliosis. Berlin, Springer, 1993, pp 267-300.
57. Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT Marques AR, Mitchell PD, Purcell JE, Ratterree MS, Straubinger RK: Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis 2001;184:870-878.
58. Peltomaa M, McHugh G, Steere AC: Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J Infect Dis 2003;187:1178-1186.
59. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, Steere AC: Treatment of early Lyme disease. Am J Med 1992;92:396-403.
60. Plorer A, Sepp N, Schmutzhard E, Krabichler S, Trobos S, Schauer G, Pahl C, Stoffler G, Fritsch P: Effects of adequate versus inadequate treatment of cutaneous manifestations of Lyme borreliosis on the incidence of late complications and late serologic status. J Invest Dermatol 1993;100:103-109.